Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Agranulocytosis as a side effect of clozapine has been reported to be associated with initial phases of treatment, i.e., first six months. Agranulocytosis with clozapine during the initial phases of treatment has been linked to genetic vulnerability in the form of variations in the human leukocyte-antigen haplotypes. However, there is limited literature on late onset agranulocytosis with clozapine and this has very rarely been linked to human leukocyte-antigen haplotypes vulnerability. In this report we review the existing data on late onset agranulocytosis with clozapine and describe the case of a young man, who developed agranulocytosis with clozapine after 35 months of treatment and was found to have genetic vulnerability in form of being positive for HLA DR4. This case highlights underlying autoimmune immune mechanism in clozapine-induced agranulocytosis and the need for frequent blood count monitoring on clozapine even after the initial 6 months of starting treatment especially in patients with genetic vulnerability to develop this condition.
Abstract
Agranulocytosis as a side effect of clozapine has been reported to be associated with initial phases of treatment, i.e., first six months. Agranulocytosis with clozapine during the initial phases of treatment has been linked to genetic vulnerability in the form of variations in the human leukocyte-antigen haplotypes. However, there is limited literature on late onset agranulocytosis with clozapine and this has very rarely been linked to human leukocyte-antigen haplotypes vulnerability. In this report we review the existing data on late onset agranulocytosis with clozapine and describe the case of a young man, who developed agranulocytosis with clozapine after 35 months of treatment and was found to have genetic vulnerability in form of being positive for HLA DR4. This case highlights underlying autoimmune immune mechanism in clozapine-induced agranulocytosis and the need for frequent blood count monitoring on clozapine even after the initial 6 months of starting treatment especially in patients with genetic vulnerability to develop this condition.
참고문헌 (42)
- Alvir JM, "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States", N Engl J Med, 329, pp.162~167 (1993)
- Hummer M, "Clozapine-induced transient white blood count disorders", J Clin Psychiatry, 55, pp.429~432 (1994)
- Atkin K, "Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland", Br J Psychiatry, 169, pp.483~488 (1996)
- Bhanji NH, "Lateonset agranulocytosis in a patient with schizophrenia after 17 months of clozapine treatment", J Clin Psychopharmacol, 23, pp.522~523 (2003)
- Cohen D, "White blood cell monitoring during long-term clozapine treatment", Am J Psychiatry, 170, pp.366~369 (2013)
- Ghaznavi S, "Rechallenging with clozapine following neutropenia:treatment options for refractory schizophrenia", Am J Psychiatry, 165, pp.813~818 (2008)
- Manfredi R, "Clozapine-related agranulocytosis associated with fever of unknown origin, protective hospitalisation, and multiple adverse events related to the administration of empiric antimicrobial treatment", Pharmacoepidemiol Drug Saf, 16, pp.1285~1289 (2007)
- Panesar N, "Late onset neutropenia with clozapine", Aust N Z J Psychiatry, 45, pp.684~ (2011)
- Raja M, "Late onset neutropenia associated with clozapine", J Clin Psychopharmacol, 31, pp.780~781 (2011)
- Raveendranathan D, "Late-onset clozapineinduced agranulocytosis in a patient with comorbid multiple sclerosis", Gen Hosp Psychiatry, 35, pp.574.e5~574.e6 (2013)
- Sedky K, "Clozapineinduced agranulocytosis after 11 years of treatment", Am J Psychiatry, 162, pp.814~ (2005)
- Silvestrini C, "A second trial of clozapine in a case of granulocytopenia", Hum Psychopharmacol, 15, pp.275~279 (2000)
- Small JG, "Rechallenge of late-onset neutropenia with clozapine", J Clin Psychopharmacol, 25, pp.185~186 (2005)
- Tamam L, "Late onset neutropenia during clozapine treatment", Psychiatry Clin Neurosci, 55, pp.547~548 (2001)
- Thompson A, "Late onset neutropenia with clozapine", Can J Psychiatry, 49, pp.647~648 (2004)
- Tourian L, "Late-onset agranulocytosis in a patient treated with clozapine and lamotrigine", J Clin Psychopharmacol, 31, pp.665~667 (2011)
- Velayudhan R, "Late onset clozapine induced agranulocytosis", Indian J Psychol Med, 36, pp.425~427 (2014)
- Corzo D, "HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapineinduced agranulocytosis", J Clin Psychiatry, 55(Suppl B), pp.149~152 (1994)
- Godleski LS, "Agranulocytosis after addition of risperidone to clozapine treatment", Am J Psychiatry, 153, pp.735~736 (1996)
- Kutscher EC, "Clozapine-induced leukopenia successfully treated with lithium", Am J Health Syst Pharm, 64, pp.2027~2031 (2007)
- Nongpiur A, "Delayed onset of clozapine-induced leucopenia", Am J Ther, 19, pp.e118~e119 (2012)
- Sénéchal A, "Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs", Encephale, 28, pp.567~569 (2002)
- Patel NC, "Sudden late onset of clozapine-induced agranulocytosis", Ann Pharmacother, 36, pp.1012~1015 (2002)
- Peacock L, "Clozapine treatment in Denmark:concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices", J Clin Psychiatry, 55, pp.44~49 (1994)
- Latif Z, "Clozapine-induced late leukopenia", Ir J Med Sci, 181, pp.139~141 (2012)
- Voulgari C, "Clozapine-induced late agranulocytosis and severe neutropenia complicated with Streptococcus pneumonia, venous thromboembolism, and allergic vasculitis in treatment-resistant female psychosis", Case Rep Med, 2015, pp.703218~ (2015)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- Husain Z, "Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine", Toxicol Appl Pharmacol, 214, pp.326~334 (2006)
- Fehsel K, "Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients", J Clin Psychopharmacol, 25, pp.419~426 (2005)
- Lieberman JA, "HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia", Arch Gen Psychiatry, 47, pp.945~948 (1990)
- Yunis JJ, "HLA associations in clozapine-induced agranulocytosis", Blood, 86, pp.1177~1183 (1995)
- Claas FH, "No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis", Drug Saf, 7(Suppl 1), pp.3~6 (1992)
- Abt K, "HLA-associations in Leponex", Clozaril (clozapine)-induced granulocytopenia and agranulocytosis. Statistical viewpoints, 1992, pp.7(Suppl 1), 10~16
- Valevski A, "HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients", Eur J Immunogenet, 25, pp.11~13 (1998)
- McKnight C, "Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C", Am J Psychiatry, 168, pp.1120~ (2011)
- Goldstein JI, "Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles", Nat Commun, 5, pp.4757~ (2014)
- Baldessarini RJ, "Clozapine. A novel antipsychotic agent", N Engl J Med, 324, pp.746~754 (1991)
- Lekhakula A, "Drug-induced agranulocytosis:experience in two university hospitals", J Med Assoc Thai, 74, pp.121~130 (1991)
- Hummer M, "Does eosinophilia predict clozapine induced neutropenia?", Psychopharmacology (Berl), 124, pp.201~204 (1996)
- Nielsen H, "Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis", J Intern Med, 234, pp.529~531 (1993)
- Sedky K, "Psychotropic medications and leukopenia", Curr Drug Targets, 7, pp.1191~1194 (2006)
- Whiskey E, "Restarting clozapine after neutropenia:evaluating the possibilities and practicalities", CNS Drugs, 21, pp.25~35 (2007)
